Free Trial

Bayer Aktiengesellschaft (BAYRY) Stock Forecast & Price Target

Bayer Aktiengesellschaft logo
$5.14 -0.22 (-4.10%)
(As of 11/20/2024 ET)

Bayer Aktiengesellschaft - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
6
Buy
0

Based on 7 Wall Street analysts who have issued ratings for Bayer Aktiengesellschaft in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 7 analysts, 1 has given a sell rating, and 6 have given a hold rating for BAYRY.

Consensus Price Target

N/A

Get the Latest News and Ratings for BAYRY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bayer Aktiengesellschaft and its competitors.

Sign Up

BAYRY Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
6 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Reduce
Reduce
Reduce
Hold

BAYRY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BAYRY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bayer Aktiengesellschaft Stock vs. The Competition

TypeBayer AktiengesellschaftMedical CompaniesS&P 500
Consensus Rating Score
1.88
2.80
2.50
Consensus RatingReduceModerate BuyModerate Buy
Predicted UpsideN/A26,931.56% Upside9.82% Upside
News Sentiment Rating
Neutral News

See Recent BAYRY News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/6/2024Bank of America
4 of 5 stars
 UpgradeUnderperform ➝ Neutral
5/30/2024The Goldman Sachs Group
2 of 5 stars
 Initiated CoverageNeutral
3/7/2024Sanford C. Bernstein
3 of 5 stars
 Reiterated RatingOutperform ➝ Market Perform
2/29/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral
1/30/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
12/18/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeHold ➝ Reduce
12/4/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
11/21/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
11/14/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
9/25/2023Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral
8/16/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
1/6/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
1/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:32 AM ET.


BAYRY Forecast - Frequently Asked Questions

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bayer Aktiengesellschaft in the last twelve months. There is currently 1 sell rating and 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" BAYRY shares.

According to analysts, Bayer Aktiengesellschaft's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Bayer Aktiengesellschaft's stock had 1 upgrade by analysts.

Bayer Aktiengesellschaft has been rated by research analysts at Bank of America in the past 90 days.

Analysts like Bayer Aktiengesellschaft less than other "medical" companies. The consensus rating for Bayer Aktiengesellschaft is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BAYRY compares to other companies.


This page (OTCMKTS:BAYRY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners